Table 4.
All HSC activity is in the CD150+ fraction of old bone marrow, reconstituted bone marrow, and day-7 cyclophosphamide/G-CSF-treated splenocytes
| Source of cells | No. donor-type cells transplanted | No. mice with long-term multilineage engraftment/no. mice total |
|---|---|---|
| Old bone marrow | ||
| CD150+ | 20 000 | 7/8 |
| CD150– | 180 000 | 0/9 |
| Mobilized splenocytes | ||
| CD150+ | 20 000 | 8/9 |
| CD150– | 180 000 | 0/10 |
| Reconstituted bone marrow | ||
| CD150+ | 20 000 | 3/4 |
| CD150– | 180 000 | 0/5 |
The indicated number of donor-type (CD45.1+) cells was transplanted intravenously into lethally irradiated recipients (CD45.2+) along with 200 000 recipient-type (CD45.2+) whole bone marrow cells. The dose of CD150+ or CD150– donor cells was based on the number of cells from each population contained in 200 000 old bone marrow, mobilized spleen, or reconstituted bone marrow cells as done in previous studies of marker expression on HSCs.3,10,13,19 Mice were considered long-term multilineage reconstituted if donor-type myeloid, B, and T cells were present for at least 16 weeks after transplantation.